Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Angiotensin II receptor blockers (ARB) are known to preserve kidney function among patients with kidney diseases and reduced renal function, but not among haemodialysis patients.

Haemodialysis patients often lose residual renal function after initiating dialysis leading to worsened quality of life, increased morbidity and mortality.

In this study an ARB is investigated in a double blind, randomised, parallel group, placebo controlled manner to see, if this ARB can save residual renal function among haemodialysis patients. Potential cardiovascular benefits of the treatment are also addressed.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Treatments: Angiotensin II Type 1 Receptor Blockers; Irbesartan

Criteria

Inclusion Criteria:

• Haemodialysis patient

• Haemodialysis treatment for maximum 12 months

• > 18 years old

• informed consent

• urine volume > 300 ml / 24 hours

• contraception if fertile woman

Exclusion Criteria:

• Systolic blood pressure < 110 mm Hg

• Able to comprehend the aims of the project and follow instructions

• Allergy to irbesartan/ACE-inhibitors/ARBs

• Myocardial infarction or unstable angina pectoris during the last 3 months

• Ejection fraction < 30 %

• Pregnancy